Disease or Syndrome – Page 153

Merck KGaA Partners with AI Techbio Caris Discovery for ADC Discovery, Up to $1.4 Billion in Milestones

2 years ago talkbio0Tagged Antibody-Drug Conjugates, Artificial Intelligence, Caris Discovery, Discover, Merck KGaA, milestones

Merck KGaA, AI techbio, Caris Discovery, Antibody-Drug Conjugates (ADC), $1.4 billion milestones, ADC discovery deal

Basilea Secures FDA Approval for Zevtera to Treat Three Types of Bacterial Infections

2 years ago talkbio0Tagged ABSSSI, Acute bacterial skin, Approved, Bacteremia due to Staphylococcus aureus, Basilea Pharmaceutica, CABP, ceftobiprole, Community-acquired bacterial pneumonia, designations, exclusivity, Priority Review, QIDP, Qualified Infectious Disease Product, skin structure infections, Track/, United States Food and Drug Administration, year, Zevtera

Basilea Pharmaceutica, Zevtera (ceftobiprole), FDA approval, Acute bacterial skin and skin structure infections (ABSSSI), Staphylococcus aureus bacteremia (SAB), Community-acquired bacterial pneumonia (CABP), Qualified Infectious Disease Product (QIDP) status, Priority Review/ Fast Track/ and QIDP designations, Ten years of exclusivity in the US

Diagonal Therapeutics Secures $128 Million Series A Funding through Innovative Antibody Agonists

2 years ago talkbio0Tagged Antibody agonism, Cells, Diagonal, Funding, Rare Diseases, switches

Diagonal Therapeutics, Series A funding, Antibody agonism, Cellular “on” switches, Rare diseases

Diagonal Therapeutics Secures $128 Million Funding to Target Rare Diseases

2 years ago talkbio0Tagged Antibodies, Blue-chip, Chronic anemia, Diagonal, Merck's, Orphan disease treatment, Rare diseases focus, research, Winrevair

Diagonal Therapeutics, Antibody biotech, $128 million funding, Rare diseases focus, Orphan disease treatment, Chronic anemia, Merck’s Winrevair related research, Blue-chip investors

Vanda’s Fanapt Secures Second FDA Approval for Treating Bipolar I Disorder

2 years ago talkbio0Tagged acute, Bipolar I disorder, Dentatorubral-Pallidoluysian Atrophy, Fanapt, iloperidone, Manic, mixed episodes, United States Food and Drug Administration, Vanda Pharmaceuticals

Fanapt, Vanda Pharmaceuticals, Bipolar I Disorder, Second FDA Nod, Iloperidone, Acute Treatment of Manic or Mixed Episodes

Verve Temporarily Halts Lead Base Editing Study Following Adverse Event, Prioritizes Alternative Therapy

2 years ago talkbio0Tagged Adverse event, Alanine Transaminase, Alternative Therapies, Cognitive function: initiation, Elevation procedure, Grade three rank, Heart-1 study, Heart-2 clinical trial, Ionizable, Lead base editing program, lipid delivery system, Pause enrollment, Phase Ib Heart-2 clinical trial, Q2 2024, SAEs, Serious adverse events, Thrombocytopenia, VERVE-101, VERVE-102

Verve Therapeutics, Lead base editing program, Adverse event, VERVE-101, Serious adverse events (SAEs), Grade 3 ALT elevation, Thrombocytopenia, Pause enrollment in Heart-1 study, Alternative therapy focus: VERVE-102, Ionizable lipid delivery system, Phase Ib Heart-2 clinical trial, Q2 2024 initiation of Heart-2 clinical trial.

Bristol Myers Squibb’s Zeposia Misses Mark in Phase 3 Crohn’s Disease Study

2 years ago talkbio0Tagged bristol-myers, Clinical Remission Endpoint Not, Crohn Disease, ozanimod, Unmet Medical Need, YELLOWSTONE Program, Zeposia

Bristol Myers Squibb, Zeposia (ozanimod), Phase 3 Trial Setback, Crohn’s Disease, Clinical Remission Endpoint Not Met, YELLOWSTONE Program, Unmet Medical Need in Crohn’s Treatment

Medicare Coverage Gap Linked to Reduced Prescription Rates for GLP-1 Weight Loss Drugs

2 years ago talkbio0Tagged Glucagon-Like Peptide 1, Health Care Costs, liraglutide, Lower prescription rates, Medicare, Mounjaro, Obesity, Saxenda, semaglutide, tirzepatide, Truveta study, Wegovy

GLP-1 drugs, Medicare coverage gap, Lower prescription rates, Obesity treatment, Semaglutide (Wegovy), Tirzepatide (Mounjaro), Liraglutide (Saxenda), Healthcare costs, Truveta study

FDA Approves Vadadustat (Vafseo) for Anemia in Chronic Kidney Disease Patients on Dialysis and Daprodustat (Jesduvroq) for Dialysis-Dependent CKD Adults

2 years ago talkbio0Tagged Anemia, Approved, Black Box Warning, Chronic Kidney Diseases, Daprodustat, Effectiveness, Hemoglobin concentration result, Jesduvroq, Oral Medication, post-marketing safety, Safety, United States Food and Drug Administration, vadadustat, Vafseo

Anemia, Chronic Kidney Disease (CKD), Vadadustat (Vafseo), Daprodustat (Jesduvroq), Oral medication, FDA approval, Hemoglobin levels, Black Box Warning, Efficacy and safety data, Post-marketing safety data

Pfizer Discontinues Phase III Trial for Sickle Cell Treatment Amid Challenges in Patient Recruitment

2 years ago talkbio0Tagged Anemia, Sickle Cell, ClinicalTrials.gov, Grail, inclacumab, Pfizer, Phase 3 Clinical Trials, Poor Accrual, Recruitment Challenges, THRIVE Program

Pfizer, Sickle Cell Disease, Phase III Study, Inclacumab, Poor Accrual, Recruitment Challenges, THRIVE Program, ClinicalTrials.gov, Gene Therapies